Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hlca.19760590412 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study.
BMC Ophthalmol
January 2025
Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
Purpose: To assess the clinical efficacy of 0.1% cyclosporine A (CsA) in dry eye patients who have shown inadequate responses to previous treatment with 0.05% CsA.
View Article and Find Full Text PDFThe cardiometabolic safety of dupilumab in atopic dermatitis: A global large-scale cohort study.
Arch Dermatol Res
January 2025
Lűbeck Institute of Experimental Dermatology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Background: A low risk of cardiovascular and metabolic outcomes was found in the randomized clinical trials of dupilumab in atopic dermatitis (AD). Dupilumab-associated real-life long-term cardiometabolic risk relative to other systemic agents is yet to be precisely investigated.
Objective: To assess the risk of cardiometabolic outcomes in patients with AD treated with dupilumab relative to those treated with methotrexate and cyclosporine.
Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology.
PLoS One
January 2025
Department of Laboratory, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, P.R. China.
Background: Systemic lupus erythematosus (SLE) is a complex and incurable autoimmune disease, so several drug remission for SLE symptoms have been developed and used at present. However, treatment varies by patient and disease activity, and existing medications for SLE were far from satisfactory. Novel drug targets to be found for SLE therapy are still needed.
View Article and Find Full Text PDFChronic urticaria treatment challenges in children.
Rev Paul Pediatr
January 2025
Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Objective: This paper aims to review the efficacy and safety of current chronic urticaria (CU) treatment in children and the existing patient-reported outcome measures (PROMs) used in this age group.
Data Source: Since there are few studies of CU in children, the authors performed a non-systematic review of published articles in English, Spanish, and Portuguese in the PubMed database in the last decade. Keywords used were (antihistamines OR omalizumab OR cyclosporine OR treatment) AND (chronic urticaria) AND (children OR adolescents).
Pharmacokinetic Boosting of Calcineurin Inhibitors in Transplantation: Pros, Cons, and Perspectives.
Ther Drug Monit
February 2025
Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France.
The concept of pharmacokinetic (PK) boosting of calcineurin inhibitors (CNI) emerged after the FDA approval of cyclosporine-A. Several studies followed, and the proof of concept was well established by the late 1990s. This also continued for the next blockbuster immunosuppressant, tacrolimus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!